{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T03:39:26Z","timestamp":1784086766976,"version":"3.55.0"},"reference-count":175,"publisher":"Elsevier","isbn-type":[{"value":"9780323900874","type":"print"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R35 HL155651"],"award-info":[{"award-number":["R35 HL155651"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/bs.acr.2022.03.006","type":"book-chapter","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T20:09:42Z","timestamp":1650485382000},"page":"167-214","source":"Crossref","is-referenced-by-count":12,"title":["Cardiac complications of cancer therapies"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.acr.2022.03.006_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2018.03.006","article-title":"The evolution of radiation therapy in treating cancer","author":"Abshire","year":"2018","journal-title":"Seminars in Oncology Nursing"},{"issue":"9","key":"10.1016\/bs.acr.2022.03.006_bb0015","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jacc.2011.05.025","article-title":"Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy","volume":"58","author":"Acar","year":"2011","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.006_bb0020","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ejhf.196","article-title":"Protective effects of spironolactone against anthracycline-induced cardiomyopathy","volume":"17","author":"Akpek","year":"2015","journal-title":"European Journal of Heart Failure"},{"issue":"7","key":"10.1016\/bs.acr.2022.03.006_bb0025","first-page":"1789","article-title":"Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis","volume":"60","author":"Arola","year":"2000","journal-title":"Cancer Research"},{"issue":"3","key":"10.1016\/bs.acr.2022.03.006_bb0030","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ijrobp.2016.07.007","article-title":"Stroke after radiation therapy for head and neck cancer: What is the risk?","volume":"96","author":"Arthurs","year":"2016","journal-title":"International Journal of Radiation Oncology Biology Physics"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.006_bb0035","doi-asserted-by":"crossref","DOI":"10.1186\/1752-1947-8-252","article-title":"Cardiotoxicity following cyclophosphamide therapy: A case report","volume":"8","author":"Atalay","year":"2014","journal-title":"Journal of Medical Case Reports"},{"issue":"20","key":"10.1016\/bs.acr.2022.03.006_bb0040","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: The CECCY trial","volume":"71","author":"Avila","year":"2018","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.006_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40959-019-0054-5","article-title":"Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors","volume":"5","author":"Bansal","year":"2019","journal-title":"Cardio-Oncology"},{"issue":"8","key":"10.1016\/bs.acr.2022.03.006_bb0050","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/17425255.2017.1351547","article-title":"Chemotherapy-induced cardiotoxicity in children","volume":"13","author":"Bansal","year":"2017","journal-title":"Expert Opinion on Drug Metabolism and Toxicology"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.006_bb0055","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1161\/CIRCRESAHA.117.312395","article-title":"Anthracycline cardiotoxicity","volume":"122","author":"Bernstein","year":"2018","journal-title":"Circulation Research"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.006_bb0060","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"British Journal of Cancer"},{"key":"10.1016\/bs.acr.2022.03.006_bb0065","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-018-0804-2","article-title":"Kinase-targeted cancer therapies: Progress, challenges and future directions","author":"Bhullar","year":"2018","journal-title":"Molecular Cancer"},{"issue":"23","key":"10.1016\/bs.acr.2022.03.006_bb0070","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","article-title":"Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies","volume":"61","author":"Bosch","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.006_bb0075","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.leukres.2013.01.021","article-title":"Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors","volume":"37","author":"Breccia","year":"2013","journal-title":"Leukemia Research"},{"issue":"3","key":"10.1016\/bs.acr.2022.03.006_bb0080","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0002-9343(81)90574-X","article-title":"Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart","volume":"70","author":"Brosius","year":"1981","journal-title":"The American Journal of Medicine"},{"issue":"4\u20135","key":"10.1016\/bs.acr.2022.03.006_bb0085","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.drup.2009.07.001","article-title":"Understanding the causes of multidrug resistance in cancer: A comparison of doxorubicin and sunitinib","volume":"12","author":"Broxterman","year":"2009","journal-title":"Drug Resistance Updates"},{"key":"10.1016\/bs.acr.2022.03.006_bb0090","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.2459\/JCM.0000000000000382","article-title":"Preventing antiblastic drug-related cardiomyopathy: Old and new therapeutic strategies","volume":"17","author":"Cadeddu","year":"2016","journal-title":"Journal of Cardiovascular Medicine"},{"key":"10.1016\/bs.acr.2022.03.006_bb0095","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/1521020","article-title":"Oxidative stress and cellular response to doxorubicin: A common factor in the complex milieu of anthracycline cardiotoxicity","volume":"2017","author":"Cappetta","year":"2017","journal-title":"Oxidative Medicine and Cellular Longevity"},{"key":"10.1016\/bs.acr.2022.03.006_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2020.00026","article-title":"Cardiotoxicity of anthracyclines","author":"Cardinale","year":"2020","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"3","key":"10.1016\/bs.acr.2022.03.006_bb0105","doi-asserted-by":"crossref","first-page":"226","DOI":"10.5301\/tj.5000507","article-title":"The roots of modern oncology: From discovery of new antitumor anthracyclines to their clinical use","volume":"102","author":"Cassinelli","year":"2016","journal-title":"Tumori"},{"issue":"7","key":"10.1016\/bs.acr.2022.03.006_bb0110","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41568-020-0256-z","article-title":"The duality of human oncoproteins: Drivers of cancer and congenital disorders","volume":"20","author":"Castel","year":"2020","journal-title":"Nature Reviews Cancer"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.006_bb0115","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCULATIONAHA.108.776831","article-title":"Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics","volume":"118","author":"Chen","year":"2008","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.006_bb0120","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ccep.2016.01.004","article-title":"Cardiac delayed rectifier potassium channels in health and disease","volume":"8","author":"Chen","year":"2016","journal-title":"Cardiac Electrophysiology Clinics"},{"issue":"3","key":"10.1016\/bs.acr.2022.03.006_bb0125","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.cjca.2014.11.020","article-title":"Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function","volume":"31","author":"Chotenimitkhun","year":"2015","journal-title":"Canadian Journal of Cardiology"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.006_bb0130","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.3390\/cells9061558","article-title":"Targeting cardiac stem cell senescence to treat cardiac aging and disease","volume":"9","author":"Cianflone","year":"2020","journal-title":"Cell"},{"issue":"3","key":"10.1016\/bs.acr.2022.03.006_bb0135","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/CRD.0000000000000183","article-title":"Cardiovascular complications of proteasome inhibitors used in multiple myeloma","volume":"26","author":"Cole","year":"2018","journal-title":"Cardiology in Review"},{"issue":"22","key":"10.1016\/bs.acr.2022.03.006_bb0140","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma","volume":"37","author":"Cornell","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.acr.2022.03.006_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.tibs.2017.11.008","article-title":"TCR signaling: Mechanisms of initiation and propagation","author":"Courtney","year":"2018","journal-title":"Trends in Biochemical Sciences"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.006_bb0150","doi-asserted-by":"crossref","first-page":"H460","DOI":"10.1152\/ajpheart.00056.2019","article-title":"Embryonic stem cell-derived exosomes inhibit doxorubicin-induced TLR4-NLRP3-mediated cell death-pyroptosis","volume":"317","author":"Dargani","year":"2019","journal-title":"American Journal of Physiology - Heart and Circulatory Physiology"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.006_bb0155","article-title":"Targeting aberrant RAS\/RAF\/MEK\/ERK signaling for cancer therapy","volume":"9","author":"Degirmenci","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.006_bb0160","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1600-065X.2012.01099.x","article-title":"NF-\u03baB and the link between inflammation and cancer","volume":"246","author":"Didonato","year":"2012","journal-title":"Immunological Reviews"},{"issue":"10","key":"10.1016\/bs.acr.2022.03.006_bb0165","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1177\/0003319714523112","article-title":"Acute cardiotoxic effects of adjuvant trastuzumab treatment and its relation to oxidative stress","volume":"65","author":"Dirican","year":"2014","journal-title":"Angiology"},{"key":"10.1016\/bs.acr.2022.03.006_bb0170","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.tox.2016.10.001","article-title":"An integrative view of cisplatin-induced renal and cardiac toxicities: Molecular mechanisms, current treatment challenges and potential protective measures","volume":"371","author":"Dugbartey","year":"2016","journal-title":"Toxicology"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.006_bb0175","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ejphar.2010.09.085","article-title":"Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies","volume":"650","author":"El-Awady","year":"2011","journal-title":"European Journal of Pharmacology"},{"issue":"5","key":"10.1016\/bs.acr.2022.03.006_bb0180","doi-asserted-by":"crossref","first-page":"509","DOI":"10.5603\/CJ.a2013.0150","article-title":"Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up","volume":"21","author":"Elitok","year":"2014","journal-title":"Cardiology Journal"},{"issue":"5","key":"10.1016\/bs.acr.2022.03.006_bb0185","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.bbmt.2018.02.005","article-title":"Haploidentical bone marrow transplantation with post-transplant cyclophosphamide using non\u2013first-degree related donors","volume":"24","author":"Elmariah","year":"2018","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1016\/bs.acr.2022.03.006_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.mrrev.2010.04.002","article-title":"Somatic gene mutation and human disease other than cancer: An update","author":"Erickson","year":"2010","journal-title":"Mutation research\u2014Reviews in mutation research"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.006_bb0195","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s10741-020-10063-9","article-title":"Oxidative stress and inflammation: Determinants of anthracycline cardiotoxicity and possible therapeutic targets","volume":"26","author":"Fabiani","year":"2021","journal-title":"Heart Failure Reviews"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.006_bb0200","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/cncr.32601","article-title":"Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-Medicare database","volume":"126","author":"Fakhri","year":"2020","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/bs.acr.2022.03.006_bb0205","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1073\/pnas.1821022116","article-title":"Ferroptosis as a target for protection against cardiomyopathy","volume":"116","author":"Fang","year":"2019","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.006_bb0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115686","article-title":"Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes","volume":"10","author":"Focaccetti","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/bs.acr.2022.03.006_bb0215","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nrc2106","article-title":"Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition","volume":"7","author":"Force","year":"2007","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/bs.acr.2022.03.006_bb0220","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-pharmtox-010919-023603","article-title":"Proteasome inhibitor drugs","volume":"60","author":"Fricker","year":"2020","journal-title":"Annual Review of Pharmacology and Toxicology"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.006_bb0225","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.hoc.2019.08.005","article-title":"Modern radiation therapy planning and delivery","volume":"33","author":"Gardner","year":"2019","journal-title":"Hematology\/Oncology Clinics of North America"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.006_bb0230","first-page":"221","article-title":"Remote ischemic pre-conditioning attenuates adverse cardiac remodeling and mortality following doxorubicin administration in mice","volume":"1","author":"Gertz","year":"2019","journal-title":"JACC: CardioOncology"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.006_bb0235","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrclinonc.2015.213","article-title":"Kinase inhibitors and monoclonal antibodies in oncology: Clinical implications","volume":"13","author":"Gharwan","year":"2016","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10.1016\/bs.acr.2022.03.006_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.102925","article-title":"Cisplatin: The first metal based anticancer drug","volume":"88","author":"Ghosh","year":"2019","journal-title":"Bioorganic Chemistry"},{"issue":"5","key":"10.1016\/bs.acr.2022.03.006_bb0245","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood.V68.5.1114.1114","article-title":"Cyclophosphamide cardiotoxicity: An analysis of dosing as a risk factor","volume":"68","author":"Goldberg","year":"1986","journal-title":"Blood"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.006_bb0250","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/archinte.1981.00340060066015","article-title":"Cardiotoxicity associated with high-dose cyclophosphamide therapy","volume":"141","author":"Gottdiener","year":"1981","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/bs.acr.2022.03.006_bb0255","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0076-6879(99)00140-8","article-title":"Inhibition of NF-\u03baB activation in vitro and in vivo: Role of 26S proteasome","volume":"300","author":"Grisham","year":"1999","journal-title":"Methods in Enzymology"},{"issue":"10","key":"10.1016\/bs.acr.2022.03.006_bb0260","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/eurheartj\/eht114","article-title":"Cardiovascular complications of radiation therapy for thoracic malignancies: The role for non-invasive imaging for detection of cardiovascular disease","volume":"35","author":"Groarke","year":"2014","journal-title":"European Heart Journal"},{"issue":"12","key":"10.1016\/bs.acr.2022.03.006_bb0265","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.bbmt.2020.08.036","article-title":"Cardiovascular events associated with chimeric antigen receptor T cell therapy: Cross-sectional FDA adverse events reporting system analysis: Cardiovascular events with CAR-T therapy","volume":"26","author":"Guha","year":"2020","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"21","key":"10.1016\/bs.acr.2022.03.006_bb0270","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): A 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"European Heart Journal"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.006_bb0275","doi-asserted-by":"crossref","first-page":"T69","DOI":"10.1530\/JME-17-0311","article-title":"40 years of IGF1: IGF1 receptor signaling pathways","volume":"61","author":"Hakuno","year":"2018","journal-title":"Journal of Molecular Endocrinology"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.006_bb0280","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1182\/bloodadvances.2019000163","article-title":"Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"4","author":"Harvey","year":"2020","journal-title":"Blood Advances"},{"issue":"15","key":"10.1016\/bs.acr.2022.03.006_bb0285","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1158\/1078-0432.CCR-09-0628","article-title":"Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training","volume":"15","author":"Haykowsky","year":"2009","journal-title":"Clinical Cancer Research"},{"issue":"12","key":"10.1016\/bs.acr.2022.03.006_bb0290","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/heartjnl-2017-312103","article-title":"Anthracycline cardiotoxicity: An update on mechanisms, monitoring and prevention","volume":"104","author":"Henriksen","year":"2018","journal-title":"Heart"},{"issue":"10","key":"10.1016\/bs.acr.2022.03.006_bb0295","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1634\/theoncologist.2012-0123","article-title":"U.S. food and drug administration approval: Peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma","volume":"17","author":"Herndon","year":"2012","journal-title":"The Oncologist"},{"issue":"8","key":"10.1016\/bs.acr.2022.03.006_bb0300","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: Cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nature Reviews Cardiology"},{"issue":"9","key":"10.1016\/bs.acr.2022.03.006_bb0305","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.mayocp.2014.05.013","article-title":"Evaluation and management of patients with heart disease and cancer: Cardio-oncology","volume":"89","author":"Herrmann","year":"2014","journal-title":"Mayo Clinic Proceedings"},{"issue":"11","key":"10.1016\/bs.acr.2022.03.006_bb0310","first-page":"774","article-title":"The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: A continual challenge","volume":"38","author":"Heusch","year":"2017","journal-title":"European Heart Journal"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.006_bb0315","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s10741-015-9502-y","article-title":"Chemotherapy-induced cardiomyopathy","volume":"20","author":"Higgins","year":"2015","journal-title":"Heart Failure Reviews"},{"key":"10.1016\/bs.acr.2022.03.006_bb0320","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.freeradbiomed.2018.09.043","article-title":"The development of the concept of ferroptosis","volume":"133","author":"Hirschhorn","year":"2019","journal-title":"Free Radical Biology and Medicine"},{"issue":"8","key":"10.1016\/bs.acr.2022.03.006_bb0325","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1073\/pnas.0830997100","article-title":"Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients","volume":"100","author":"Hodi","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"8","key":"10.1016\/bs.acr.2022.03.006_bb0330","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"37","key":"10.1016\/bs.acr.2022.03.006_bb0335","article-title":"NAD+ supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer's disease via cGAS-STING","volume":"118","author":"Hou","year":"2021","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"S1","key":"10.1016\/bs.acr.2022.03.006_bb0340","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.21037\/tlcr.2017.12.10","article-title":"Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: A meta-analysis","volume":"6","author":"Hu","year":"2017","journal-title":"Translational Lung Cancer Research"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.006_bb0345","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1172\/JCI72931","article-title":"Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation","volume":"124","author":"Ichikawa","year":"2014","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/bs.acr.2022.03.006_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2018.12.018","article-title":"Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: Old drug with a new vision","author":"Iqubal","year":"2019","journal-title":"Life Sciences"},{"issue":"19","key":"10.1016\/bs.acr.2022.03.006_bb0355","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"10.1016\/bs.acr.2022.03.006_bb0360","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ijrobp.2018.10.025","article-title":"Radiation dose-response for risk of myocardial infarction in breast cancer survivors","volume":"103","author":"Jacobse","year":"2019","journal-title":"International Journal of Radiation Oncology Biology Physics"},{"issue":"7","key":"10.1016\/bs.acr.2022.03.006_bb0365","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/CJI.0000000000000239","article-title":"Autoimmune myocarditis caused by immune checkpoint inhibitors treated with antithymocyte globulin","volume":"41","author":"Jain","year":"2018","journal-title":"Journal of Immunotherapy"},{"issue":"18","key":"10.1016\/bs.acr.2022.03.006_bb0370","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"23","key":"10.1016\/bs.acr.2022.03.006_bb0375","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1200\/JCO.2015.65.6603","article-title":"Exercise and risk of cardiovascular events in women with nonmetastatic breast cancer","volume":"34","author":"Jones","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"5781","key":"10.1016\/bs.acr.2022.03.006_bb0380","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1126\/science.1127196","article-title":"A topoisomerase II\u03b2-mediated dsDNA break required for regulated transcription","volume":"312","author":"Ju","year":"2006","journal-title":"Science"},{"issue":"11","key":"10.1016\/bs.acr.2022.03.006_bb0385","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy","volume":"48","author":"Kalay","year":"2006","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.006_bb0390","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1042\/BJ20050285","article-title":"Doxorubicin activates nuclear factor of activated T-lymphocytes and Fas ligand transcription: Role of mitochondrial reactive oxygen species and calcium","volume":"389","author":"Kalivendi","year":"2005","journal-title":"Biochemical Journal"},{"issue":"9","key":"10.1016\/bs.acr.2022.03.006_bb0395","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"The Lancet Oncology"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.006_bb0400","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1667\/RR14406.1","article-title":"A review of radiation-induced coagulopathy and new findings to support potential prevention strategies and treatments","volume":"186","author":"Kennedy","year":"2016","journal-title":"Radiation Research"},{"issue":"8","key":"10.1016\/bs.acr.2022.03.006_bb0405","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkel\u00e4","year":"2006","journal-title":"Nature Medicine"},{"issue":"23","key":"10.1016\/bs.acr.2022.03.006_bb0410","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/CIRCULATIONAHA.112.100560","article-title":"Cancer therapy-induced cardiac toxicity in early breast cancer addressing the unresolved issues","volume":"126","author":"Khouri","year":"2012","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.006_bb0415","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","article-title":"Cardiotoxicity of fluoropyrimidines in different schedules of administration: A prospective study","volume":"134","author":"Kosmas","year":"2008","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.006_bb0420","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1124\/mol.62.4.888","article-title":"Unexpected anthracycline-mediated alterations in iron-regulatory protein-RNA-binding activity: The iron and copper complexes of anthracyclines decrease RNA-binding activity","volume":"62","author":"Kwok","year":"2002","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/bs.acr.2022.03.006_bb0425","doi-asserted-by":"crossref","DOI":"10.1021\/acs.chemrestox.9b00387","article-title":"Cardiovascular toxicity induced by kinase inhibitors: Mechanisms and preclinical approaches","author":"Lamore","year":"2020","journal-title":"Chemical Research in Toxicology"},{"issue":"10","key":"10.1016\/bs.acr.2022.03.006_bb0430","doi-asserted-by":"crossref","DOI":"10.1007\/s11883-019-0800-z","article-title":"Statins in the prevention and treatment of heart failure: A review of the evidence","volume":"21","author":"Lee","year":"2019","journal-title":"Current Atherosclerosis Reports"},{"issue":"7","key":"10.1016\/bs.acr.2022.03.006_bb0435","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.006_bb0440","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-00075-1","article-title":"Candidate gene association studies of anthracycline-induced cardiotoxicity: A systematic review and meta-analysis","volume":"7","author":"Leong","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/bs.acr.2022.03.006_bb0445","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.redox.2015.09.007","article-title":"Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors","volume":"6","author":"Le\u00f3n-Mateos","year":"2015","journal-title":"Redox Biology"},{"issue":"9","key":"10.1016\/bs.acr.2022.03.006_bb0450","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"The Lancet. Oncology"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.006_bb0455","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1440-1681.2009.05323.x","article-title":"Cisplatin compromises myocardial contractile function and mitochondrial ultrastructure: Role of endoplasmic reticulum stress","volume":"37","author":"Ma","year":"2010","journal-title":"Clinical and Experimental Pharmacology and Physiology"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.006_bb0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-020-0527-z","article-title":"Role of STAT3 signaling pathway in breast cancer","volume":"18","author":"Ma","year":"2020","journal-title":"Cell Communication and Signaling"},{"issue":"7 Suppl","key":"10.1016\/bs.acr.2022.03.006_bb0465","first-page":"33","article-title":"Toxicity of 5-fluorouracil","volume":"13","author":"Macdonald","year":"1999","journal-title":"Oncology"},{"key":"10.1016\/bs.acr.2022.03.006_bb0470","series-title":"XPharm: The comprehensive pharmacology reference","first-page":"1","article-title":"Dexrazoxane","author":"Mack","year":"2007"},{"issue":"type II","key":"10.1016\/bs.acr.2022.03.006_bb0475","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.2459\/JCM.0000000000000376","article-title":"Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy","volume":"17","author":"Madeddu","year":"2016","journal-title":"Journal of Cardiovascular Medicine"},{"key":"10.1016\/bs.acr.2022.03.006_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinbiochem.2004.05.006","article-title":"Tyrosine kinase inhibitors in cancer therapy","author":"Madhusudan","year":"2004","journal-title":"Clinical Biochemistry"},{"issue":"16","key":"10.1016\/bs.acr.2022.03.006_bb0485","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"Journal of the American College of Cardiology"},{"issue":"26","key":"10.1016\/bs.acr.2022.03.006_bb0490","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.2174\/138161210793176446","article-title":"Drug-related cardiotoxicity for the treatment of haematological malignancies in elderly","volume":"16","author":"Malato","year":"2012","journal-title":"Current Pharmaceutical Design"},{"issue":"5","key":"10.1016\/bs.acr.2022.03.006_bb0495","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2165\/00002018-200124050-00001","article-title":"Evaluation of drug-induced QT interval prolongation: Implications for drug approval and labelling","volume":"24","author":"Malik","year":"2001","journal-title":"Drug Safety"},{"key":"10.1016\/bs.acr.2022.03.006_bb0500","doi-asserted-by":"crossref","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","author":"Manning","year":"2002","journal-title":"Science"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.006_bb0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FJC.0000000000000247","article-title":"Pharmacologic inhibition of the NLRP3 inflammasome preserves cardiac function after ischemic and nonischemic injury in the mouse","volume":"66","author":"Marchetti","year":"2015","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.006_bb0510","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","article-title":"Anthracycline chemotherapy and cardiotoxicity","volume":"31","author":"McGowan","year":"2017","journal-title":"Cardiovascular Drugs and Therapy"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.006_bb0515","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41420-019-0182-6","article-title":"Transcriptomic profiling reveals p53 as a key regulator of doxorubicin-induced cardiotoxicity","volume":"5","author":"McSweeney","year":"2019","journal-title":"Cell Death Discovery"},{"key":"10.1016\/bs.acr.2022.03.006_bb0520","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.yjmcc.2019.08.009","article-title":"Doxorubicin induces cardiomyocyte pyroptosis via the TINCR-mediated posttranscriptional stabilization of NLR family pyrin domain containing 3","volume":"136","author":"Meng","year":"2019","journal-title":"Journal of Molecular and Cellular Cardiology"},{"issue":"9","key":"10.1016\/bs.acr.2022.03.006_bb0525","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1634\/theoncologist.12-9-1124","article-title":"Early epirubicin-induced myocardial dysfunction revealed by serial tissue doppler echocardiography: Correlation with inflammatory and oxidative stress markers","volume":"12","author":"Mercuro","year":"2007","journal-title":"The Oncologist"},{"key":"10.1016\/bs.acr.2022.03.006_bb0530","doi-asserted-by":"crossref","DOI":"10.1186\/s43042-019-0035-0","article-title":"Exploring receptor tyrosine kinases-inhibitors in cancer treatments","author":"Metibemu","year":"2019","journal-title":"Egyptian Journal of Medical Human Genetics"},{"issue":"10106","key":"10.1016\/bs.acr.2022.03.006_bb0535","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(17)31071-1","article-title":"Heart failure","volume":"390","author":"Metra","year":"2017","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.006_bb0540","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2119\/molmed.2014.00243","article-title":"Role of Interleukin-1 in radiation-induced cardiomyopathy","volume":"21","author":"Mezzaroma","year":"2015","journal-title":"Molecular Medicine"},{"key":"10.1016\/bs.acr.2022.03.006_bb0545","doi-asserted-by":"crossref","DOI":"10.1097\/HCO.0000000000000404","article-title":"Radiotherapy, chemotherapy and atherosclerosis","author":"Min","year":"2017","journal-title":"Current Opinion in Cardiology"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.006_bb0550","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.110.165860","article-title":"Pharmacological foundations of cardio-oncology","volume":"334","author":"Minotti","year":"2010","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"23","key":"10.1016\/bs.acr.2022.03.006_bb0555","first-page":"8422","article-title":"Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy","volume":"61","author":"Minotti","year":"2001","journal-title":"Cancer Research"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.006_bb0560","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/toxsci\/kfu233","article-title":"Molecular mechanisms of acrolein toxicity: Relevance to human disease","volume":"143","author":"Moghe","year":"2015","journal-title":"Toxicological Sciences"},{"key":"10.1016\/bs.acr.2022.03.006_bb0565","doi-asserted-by":"crossref","DOI":"10.1097\/CRD.0000000000000239","article-title":"Cardiotoxicity of cancer therapies","author":"Mondal","year":"2019","journal-title":"Cardiology in Review"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.006_bb0570","first-page":"541","article-title":"Should trastuzumab be administered concomitantly with anthracycline in women with early, HER2-positive breast cancer?","volume":"3","author":"Montemurro","year":"2014","journal-title":"Translational Cancer Research"},{"issue":"8","key":"10.1016\/bs.acr.2022.03.006_bb0575","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nrc3090","article-title":"Cyclin D as a therapeutic target in cancer","volume":"11","author":"Musgrove","year":"2011","journal-title":"Nature Reviews Cancer"},{"issue":"21","key":"10.1016\/bs.acr.2022.03.006_bb0580","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1111\/bph.13643","article-title":"Trastuzumab cardiotoxicity: From clinical trials to experimental studies","volume":"174","author":"Nemeth","year":"2017","journal-title":"British Journal of Pharmacology"},{"issue":"16","key":"10.1016\/bs.acr.2022.03.006_bb0585","doi-asserted-by":"crossref","first-page":"7727","DOI":"10.1073\/pnas.91.16.7727","article-title":"A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity","volume":"91","author":"Nishikawa","year":"1994","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.acr.2022.03.006_bb0590","doi-asserted-by":"crossref","DOI":"10.1038\/nrc2608","article-title":"DNA topoisomerase II and its growing repertoire of biological functions","author":"Nitiss","year":"2009","journal-title":"Nature Reviews Cancer"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.006_bb0595","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.yjmcc.2012.03.006","article-title":"Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies","volume":"52","author":"Octavia","year":"2012","journal-title":"Journal of Molecular and Cellular Cardiology"},{"key":"10.1016\/bs.acr.2022.03.006_bb0600","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","author":"O'Donnell","year":"2019","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.006_bb0605","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1634\/theoncologist.2016-0289","article-title":"Modern management of anthracycline-induced cardiotoxicity in lymphoma patients: Low occurrence of cardiotoxicity with comprehensive assessment and tailored substitution by nonpegylated liposomal doxorubicin","volume":"22","author":"Olivieri","year":"2017","journal-title":"The Oncologist"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.006_bb0610","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.hoc.2019.08.011","article-title":"Modern brachytherapy","volume":"33","author":"Otter","year":"2019","journal-title":"Hematology\/Oncology Clinics of North America"},{"issue":"8","key":"10.1016\/bs.acr.2022.03.006_bb0615","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.amjcard.2019.01.013","article-title":"Targeted cancer therapies with pericardial effusions requiring pericardiocentesis focusing on immune checkpoint inhibitors","volume":"123","author":"Palaskas","year":"2019","journal-title":"American Journal of Cardiology"},{"issue":"25","key":"10.1016\/bs.acr.2022.03.006_bb0620","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1016\/j.jacc.2007.02.060","article-title":"Potentiation of doxorubicin cardiotoxicity by iron loading in a rodent model","volume":"49","author":"Panjrath","year":"2007","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/bs.acr.2022.03.006_bb0625","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaa013","article-title":"Cardiotoxicity\u2019: Time to define new targets?","author":"Pardo Sanz","year":"2020","journal-title":"European Heart Journal"},{"issue":"12","key":"10.1016\/bs.acr.2022.03.006_bb0630","article-title":"Interventions for the treatment of oral cavity and oropharyngeal cancer: Chemotherapy","volume":"2021","author":"Parmar","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.006_bb0635","first-page":"101","article-title":"Tyrosine kinase\u2014Role and significance in cancer","volume":"1","author":"Paul","year":"2012","journal-title":"International Journal of Medical Sciences"},{"issue":"5","key":"10.1016\/bs.acr.2022.03.006_bb0640","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s11897-017-0353-9","article-title":"Prevention of chemotherapy induced cardiomyopathy","volume":"14","author":"Payne","year":"2017","journal-title":"Current Heart Failure Reports"},{"issue":"8","key":"10.1016\/bs.acr.2022.03.006_bb0645","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-breast): A randomized trial for the prevention of trastuzumab-associated cardiotoxicity","volume":"35","author":"Pituskin","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1016\/bs.acr.2022.03.006_bb0650","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3390\/cancers12030731","article-title":"Tyrosine kinase inhibitors in cancer: Breakthrough and challenges of targeted therapy","volume":"12","author":"Pottier","year":"2020","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.006_bb0655","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.006_bb0660","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41568-020-00308-y","article-title":"The rediscovery of platinum-based cancer therapy","volume":"21","author":"Rottenberg","year":"2021","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/bs.acr.2022.03.006_bb0665","doi-asserted-by":"crossref","DOI":"10.1111\/j.1600-065X.2009.00770.x","article-title":"CD28 and CTLA-4 coreceptor expression and signal transduction","author":"Rudd","year":"2009","journal-title":"Immunological Reviews"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.006_bb0670","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s11897-021-00519-w","article-title":"The interplay between autophagy and senescence in anthracycline cardiotoxicity","volume":"18","author":"Russo","year":"2021","journal-title":"Current Heart Failure Reports"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.006_bb0675","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1517\/14740330902733961","article-title":"Fluoropyrimidine-associated cardiotoxicity: Revisited","volume":"8","author":"Saif","year":"2009","journal-title":"Expert Opinion on Drug Safety"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.006_bb0680","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1517\/14728222.2011.645805","article-title":"Targeting the MAPKRASRAF signaling pathway in cancer therapy","volume":"16","author":"Santarpia","year":"2012","journal-title":"Expert Opinion on Therapeutic Targets"},{"key":"10.1016\/bs.acr.2022.03.006_bb0685","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918780140","article-title":"5-fluorouracil and cardiotoxicity: A review","volume":"10","author":"Sara","year":"2018","journal-title":"Therapeutic Advances in Medical Oncology"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.006_bb0690","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/0002-9343(87)90212-9","article-title":"Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography","volume":"82","author":"Schwartz","year":"1987","journal-title":"The American Journal of Medicine"},{"issue":"3","key":"10.1016\/bs.acr.2022.03.006_bb0695","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1021\/ml3002852","article-title":"The structure of anthracycline derivatives determines their subcellular localization and cytotoxic activity","volume":"4","author":"Shaul","year":"2013","journal-title":"ACS Medicinal Chemistry Letters"},{"issue":"11","key":"10.1016\/bs.acr.2022.03.006_bb0700","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","article-title":"Integrated safety profile of single-agent carfilzomib: Experience from 526 patients enrolled in 4 phase II clinical studies","volume":"98","author":"Siegel","year":"2013","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.006_bb0705","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA: a Cancer Journal for Clinicians"},{"key":"10.1016\/bs.acr.2022.03.006_bb0710","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ejmech.2018.04.001","article-title":"Therapeutic journery of nitrogen mustard as alkylating anticancer agents: Historic to future perspectives","volume":"151","author":"Singh","year":"2018","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.acr.2022.03.006_bb0715","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/1261270","article-title":"Ferulic acid against cyclophosphamide-induced heart toxicity in mice by inhibiting NF-B pathway","volume":"2016","author":"Song","year":"2016","journal-title":"Evidence-based Complementary and Alternative Medicine"},{"issue":"5","key":"10.1016\/bs.acr.2022.03.006_bb0720","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/mpo.2950090502","article-title":"Cardiac changes with cyclophosphamide","volume":"9","author":"Steinherz","year":"1981","journal-title":"Medical and Pediatric Oncology"},{"key":"10.1016\/bs.acr.2022.03.006_bb0725","doi-asserted-by":"crossref","DOI":"10.1136\/heartjnl-2020-318083","article-title":"Cardiotoxicities of novel cancer immunotherapies","author":"Stein-Merlob","year":"2021","journal-title":"Heart"},{"issue":"10","key":"10.1016\/bs.acr.2022.03.006_bb0730","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.clon.2013.06.012","article-title":"Understanding radiation-induced cardiovascular damage and strategies for intervention","volume":"25","author":"Stewart","year":"2013","journal-title":"Clinical Oncology"},{"issue":"11","key":"10.1016\/bs.acr.2022.03.006_bb0735","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.006_bb0740","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1200\/JCO.1997.15.4.1333","article-title":"Delayed administration of dexrazoxane provides cordiaprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy","volume":"15","author":"Swain","year":"1997","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.006_bb0745","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1200\/JCO.1997.15.4.1318","article-title":"Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer","volume":"15","author":"Swain","year":"1997","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1016\/bs.acr.2022.03.006_bb0750","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.132747","article-title":"Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity","volume":"5","author":"Tadokoro","year":"2020","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.006_bb0755","first-page":"47","article-title":"Carvedilol administration can prevent doxorubicin-induced cardiotoxicity: A double-blind randomized trial","volume":"134","author":"Tashakori Beheshti","year":"2016","journal-title":"Cardiology (Switzerland)"},{"key":"10.1016\/bs.acr.2022.03.006_bb0760","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2015.00039","article-title":"Radiation-induced heart disease: Pathologic abnormalities and putative mechanisms","volume":"5","author":"Taunk","year":"2015","journal-title":"Frontiers in Oncology"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.006_bb0765","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00018-002-8417-7","article-title":"Evidence of undiscovered cell regulatory mechanisms: Phosphoproteins and protein kinases in mitochondria","volume":"59","author":"Thomson","year":"2002","journal-title":"Cellular and Molecular Life Sciences"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.006_bb0770","doi-asserted-by":"crossref","first-page":"510","DOI":"10.4103\/0973-1482.106526","article-title":"Antimetabolites: Established cancer therapy","volume":"8","author":"Tiwari","year":"2012","journal-title":"Journal of Cancer Research and Therapeutics"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.006_bb0775","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00280-010-1372-3","article-title":"A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer","volume":"67","author":"Tolcher","year":"2011","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.006_bb0780","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrcardio.2017.161","article-title":"The NLRP3 inflammasome in acute myocardial infarction","volume":"15","author":"Toldo","year":"2018","journal-title":"Nature Reviews Cardiology"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.006_bb0785","doi-asserted-by":"crossref","first-page":"H1553","DOI":"10.1152\/ajpheart.00158.2018","article-title":"Inflammasome, pyroptosis, and cytokines in myocardial ischemia-reperfusion injury","volume":"315","author":"Toldo","year":"2018","journal-title":"American Journal of Physiology-Heart and Circulatory Physiology"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.006_bb0790","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1021\/cb500870a","article-title":"Targeting conformational plasticity of protein kinases","volume":"10","author":"Tong","year":"2015","journal-title":"ACS Chemical Biology"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.006_bb0795","doi-asserted-by":"crossref","DOI":"10.1038\/s41698-018-0056-z","article-title":"Cardiotoxicity with vascular endothelial growth factor inhibitor therapy","volume":"2","author":"Touyz","year":"2018","journal-title":"NPJ Precision Oncology"},{"issue":"11","key":"10.1016\/bs.acr.2022.03.006_bb0800","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1006\/cyto.1999.0497","article-title":"Differential regulation by IL-4 and IL-10 of radiation-induced IL-6 and IL-8 production and ICAM-1 expression by human endothelial cells","volume":"11","author":"Van Der Meeren","year":"1999","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.006_bb0805","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/clpt.2013.201","article-title":"Topoisomerase 2\u03b2: A promising molecular target for primary prevention of anthracycline-induced cardiotoxicity","volume":"95","author":"Vejpongsa","year":"2014","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/bs.acr.2022.03.006_bb0810","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.leukres.2017.05.002","article-title":"A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia","volume":"60","author":"Verstovsek","year":"2017","journal-title":"Leukemia Research"},{"key":"10.1016\/bs.acr.2022.03.006_bb0815","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: From T cell basic science to clinical practice","author":"Waldman","year":"2020","journal-title":"Nature Reviews Immunology"},{"issue":"3","key":"10.1016\/bs.acr.2022.03.006_bb0820","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF00273384","article-title":"Anthracycline analogs the past, present, and future","volume":"18","author":"Weiss","year":"1986","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.006_bb0825","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1124\/mol.119.115725","article-title":"Insights into doxorubicin-induced cardiotoxicity: Molecular mechanisms, preventive strategies, and early monitoring","volume":"96","author":"Wenningmann","year":"2019","journal-title":"Molecular Pharmacology"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.006_bb0830","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nature Immunology"},{"issue":"8","key":"10.1016\/bs.acr.2022.03.006_bb0835","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nature Reviews Immunology"},{"issue":"7","key":"10.1016\/bs.acr.2022.03.006_bb0840","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-020-00931-w","article-title":"Proteasome inhibitor-related cardiotoxicity: Mechanisms, diagnosis, and management","volume":"22","author":"Wu","year":"2020","journal-title":"Current Oncology Reports"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.006_bb0845","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087671","article-title":"Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: A systematic review and meta-analysis","volume":"9","author":"Xiao","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.006_bb0850","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1124\/mol.105.013383","article-title":"Molecular pharmacology of the interaction of anthracyclines with iron","volume":"68","author":"Xu","year":"2005","journal-title":"Molecular Pharmacology"},{"issue":"24","key":"10.1016\/bs.acr.2022.03.006_bb0855","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.006_bb0860","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1152\/physrev.00009.2003","article-title":"Preconditioning the myocardium: From cellular physiology to clinical cardiology","volume":"83","author":"Yellon","year":"2003","journal-title":"Physiological Reviews"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.006_bb0865","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1681\/ASN.2019020117","article-title":"Arterial stiffness in the heart disease of CKD","volume":"30","author":"Zanoli","year":"2019","journal-title":"Journal of the American Society of Nephrology"},{"issue":"11","key":"10.1016\/bs.acr.2022.03.006_bb0870","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nature Medicine"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.006_bb0875","first-page":"35","article-title":"The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity","volume":"3","author":"Zhang","year":"2021","journal-title":"JACC: CardioOncology"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.006_bb0880","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1471-4914(01)02217-1","article-title":"Receptor tyrosine kinases as targets for anticancer drugs","volume":"8","author":"Zwick","year":"2002","journal-title":"Trends in Molecular Medicine"}],"container-title":["Advances in Cancer Research","Strategies to Mitigate the Toxicity of Cancer Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065230X22000392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065230X22000392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T04:07:40Z","timestamp":1762229260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065230X22000392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9780323900874"],"references-count":175,"URL":"https:\/\/doi.org\/10.1016\/bs.acr.2022.03.006","relation":{},"ISSN":["0065-230X"],"issn-type":[{"value":"0065-230X","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}